Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Aging, Endothelial Dysfunction, Cellular Senescence
Interventions: Fisetin, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 65 Years and older
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions: Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d); Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Schizophrenia
Interventions: Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d; Drug
Lead sponsor: Donald C. Goff, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: Augusta, Georgia • Fall River, Massachusetts • Grand Rapids, Michigan + 6 more

Conditions: Diabetes, Peripheral Neuropathy, Pain
Interventions: lidocaine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lupus Nephritis
Interventions: Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Covina, California • La Jolla, California • Los Angeles, California + 5 more

Conditions: Obesity
Interventions: Phentermine-Topiramate Extended Release, Placebo, Online support system; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: ALXN1007, Placebo; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: beta3-adrenergic receptor agonist; Drug
Lead sponsor: Aaron Cypess; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fear Conditioning
Interventions: PF-04457845, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Hyperlipidemia
Interventions: Placebo, Second Formulation, Third Formulation; Dietary Supplement
Lead sponsor: Healthy Drink Discoveries, Inc.; Other
Eligibility: 20 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Radiation-induced Dermatitis
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Exercise-Induced Asthma
Interventions: Oglemilast, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Los Angeles, California • North Dartmouth, Massachusetts

Conditions: STGD1, Stargardt Disease 1
Interventions: Tinlarebant, Placebo; Drug
Lead sponsor: Belite Bio, Inc; Industry
Eligibility: 12 Years to 20 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more

Conditions: Hydrocortisone, Depression, Healthy Volunteers
Interventions: Hydrocortisone Oral, Placebo Oral Tablet; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV-1-infection
Interventions: B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 66
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo; Behavioral · Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Traumatic Brain Injury
Interventions: Placebo, Sertraline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo; Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Conditions: Cognitive Change, Achievement, Macular Pigmentation
Interventions: Active supplement, Placebo control; Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 8 Years to 10 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Focal Dystonia
Interventions: Topical acetyl hexapeptide-8, Placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Knee Pain
Interventions: Photobiomodulation therapy (PBM) device, Sham PBM device; Device
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
Interventions: LY4560736, Placebo, Florbetapir F18, Florbetaben F 18; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Anaheim, California • Irvine, California • Los Alamitos, California + 10 more

Conditions: Allergic Conjunctivitis
Interventions: bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Irvine, California

Search by objective public record fields.

Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms

Lidocaine for Diabetic Peripheral Neuropathy

A Study of Guselkumab in Participants With Active Lupus Nephritis

Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Cannabinoid Augmentation of Fear Response in Humans

A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

Study of Oglemilast for the Prevention of Asthma.

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Exploring the Effects of Corticosteroids on the Human Hippocampus

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Enhancing Children's Cognitive Function and Achievement Through Carotenoid Consumption

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

Acetyl Hexapeptide-8 for Blepharospasm

Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis (EPIC-KO)

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients